CD47-SIRPα在食管癌中的研究进展
Research Progress of CD47-SIRPα in Esophageal Cancer
DOI: 10.12677/acm.2025.154951, PDF,   
作者: 程迎华*：延安大学医学院，陕西 延安；刘 虎#：延安大学附属医院心胸外科，陕西 延安
关键词: CD47；SIRPα；食管癌；免疫治疗；CD47； SIRPα； Esophageal Cancer； Immunotherapy
摘要: 食管癌的发生、发展与许多因素有关，其中免疫系统发挥重要作用。CD47-SIRPα是PD-1/PD-L1，CTLA4之后的又一个免疫检查点，已经证明在多种血液系统肿瘤与实体瘤中高表达，通过产生抑制性信号阻止巨噬细胞吞噬癌细胞。本文针对其在食管癌中的表达、与患者预后的关系、免疫治疗进行综述，通过本文的阐述，食管癌中的CD47-SIRPα同样是高表达，高CD47或高SIRPα都是导致食管癌患者预后不良的因素，抗CD47抗体与人源性食管癌细胞、人源性食管癌裸鼠模型有一定的结合活性。
Abstract: The occurrence and development of esophageal cancer are related to many factors, among which the immune system plays an important role. CD47-SIRPα is another immune checkpoint after PD-1/PD-L1 and CTLA4. It has been proved to be highly expressed in various hematological malignancies and solid tumors. It inhibits macrophage phagocytosis of cancer cells by generating inhibitory signals. This article reviews the expression of CD47-SIRPα in esophageal cancer, its relationship with the prognosis of patients, and immunotherapy. Through the elaboration of this article, CD47-SIRPα is also highly expressed in esophageal cancer. High CD47 or high SIRPα are both factors contributing to poor prognosis of patients with esophageal cancer, Anti-CD47 antibodies have certain binding activity with human esophageal cancer cells and human esophageal cancer nude mouse models.
文章引用：程迎华, 刘虎. CD47-SIRPα在食管癌中的研究进展[J]. 临床医学进展, 2025, 15(4): 434-441. https://doi.org/10.12677/acm.2025.154951

参考文献

[1] Zhao, Y., Zhao, H., Zhao, M., Yu, Y., Qi, X., Wang, J., et al. (2024) Latest Insights into the Global Epidemiological Features, Screening, Early Diagnosis and Prognosis Prediction of Esophageal Squamous Cell Carcinoma. World Journal of Gastroenterology, 30, 2638-2656. [Google Scholar] [CrossRef] [PubMed]
[2] Deboever, N., Jones, C.M., Yamashita, K., Ajani, J.A. and Hofstetter, W.L. (2024) Advances in Diagnosis and Management of Cancer of the Esophagus. BMJ, 385, e074962. [Google Scholar] [CrossRef] [PubMed]
[3] 冷雪峰, 罗启余, 韩泳涛. 晚期食管癌免疫治疗药物及临床试验进展[J]. 中国胸心血管外科临床杂志, 2020, 27(7): 834-839.
[4] Brown, E., Hooper, L., Ho, T. and Gresham, H. (1990) Integrin-Associated Protein: A 50-Kd Plasma Membrane Antigen Physically and Functionally Associated with Integrins. The Journal of cell biology, 111, 2785-2794. [Google Scholar] [CrossRef] [PubMed]
[5] Zhao, H., Song, S., Ma, J., Yan, Z., Xie, H., Feng, Y., et al. (2022) CD47 as a Promising Therapeutic Target in Oncology. Frontiers in Immunology, 13, Article ID: 757480. [Google Scholar] [CrossRef] [PubMed]
[6] Brooke, G., Holbrook, J.D., Brown, M.H. and Barclay, A.N. (2004) Human Lymphocytes Interact Directly with CD47 through a Novel Member of the Signal Regulatory Protein (SIRP) Family. The Journal of Immunology, 173, 2562-2570. [Google Scholar] [CrossRef] [PubMed]
[7] Hayat, S.M.G., Bianconi, V., Pirro, M., Jaafari, M.R., Hatamipour, M. and Sahebkar, A. (2019) CD47: Role in the Immune System and Application to Cancer Therapy. Cellular Oncology, 43, 19-30. [Google Scholar] [CrossRef] [PubMed]
[8] Liu, Y., Weng, L., Wang, Y., Zhang, J., Wu, Q., Zhao, P., et al. (2024) Deciphering the Role of CD47 in Cancer Immunotherapy. Journal of Advanced Research, 63, 129-158. [Google Scholar] [CrossRef] [PubMed]
[9] Barclay, A.N. and Brown, M.H. (2006) The SIRP Family of Receptors and Immune Regulation. Nature Reviews Immunology, 6, 457-464. [Google Scholar] [CrossRef] [PubMed]
[10] Logtenberg, M.E.W., Scheeren, F.A. and Schumacher, T.N. (2020) The CD47-SIRPα Immune Checkpoint. Immunity, 52, 742-752. [Google Scholar] [CrossRef] [PubMed]
[11] Ratnikova, N.M., Lezhnin, Y.N., Frolova, E.I., Kravchenko, J.E. and Chumakov, S.P. (2017) CD47 Receptor as a Primary Target for Cancer Therapy. Molecular Biology, 51, 216-225. [Google Scholar] [CrossRef] 
[12] Chao, M.P., Weissman, I.L. and Majeti, R. (2012) The CD47-SIRPα Pathway in Cancer Immune Evasion and Potential Therapeutic Implications. Current Opinion in Immunology, 24, 225-232. [Google Scholar] [CrossRef] [PubMed]
[13] Willingham, S.B., Volkmer, J., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., et al. (2012) The CD47-Signal Regulatory Protein Alpha (SIRPα) Interaction Is a Therapeutic Target for Human Solid Tumors. Proceedings of the National Academy of Sciences, 109, 6662-6667. [Google Scholar] [CrossRef] [PubMed]
[14] Olaoba, O.T., Ayinde, K.S., Lateef, O.M., Akintubosun, M.O., Lawal, K.A. and Adelusi, T.I. (2023) Is the New Angel Better than the Old Devil? Challenges and Opportunities in CD47-SIRPα-Based Cancer Therapy. Critical Reviews in Oncology/Hematology, 184, Article ID: 103939. [Google Scholar] [CrossRef] [PubMed]
[15] Murata, Y., Kotani, T., Ohnishi, H. and Matozaki, T. (2014) The CD47-SIRP Signalling System: Its Physiological Roles and Therapeutic Application. Journal of Biochemistry, 155, 335-344. [Google Scholar] [CrossRef] [PubMed]
[16] Maimaitiyiming, H., Norman, H., Zhou, Q. and Wang, S. (2015) CD47 Deficiency Protects Mice from Diet-Induced Obesity and Improves Whole Body Glucose Tolerance and Insulin Sensitivity. Scientific Reports, 5, Article No. 8846. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, H., Li, F., Yang, Y., Chen, J. and Hu, X. (2015) SIRP/CD47 Signaling in Neurological Disorders. Brain Research, 1623, 74-80. [Google Scholar] [CrossRef] [PubMed]
[18] Zheng, F., Zhang, W., Yang, B. and Chen, M. (2022) Multi-Omics Profiling Identifies C1QA/B+ Macrophages with Multiple Immune Checkpoints Associated with Esophageal Squamous Cell Carcinoma (ESCC) Liver Metastasis. Annals of Translational Medicine, 10, 1249-1249. [Google Scholar] [CrossRef] [PubMed]
[19] Koga, N., Hu, Q., Sakai, A., Takada, K., Nakanishi, R., Hisamatsu, Y., et al. (2021) Clinical Significance of Signal Regulatory Protein Alpha (SIRPα) Expression in Esophageal Squamous Cell Carcinoma. Cancer Science, 112, 3018-3028. [Google Scholar] [CrossRef] [PubMed]
[20] Strizova, Z., Vachtenheim, J., Snajdauf, M., Lischke, R., Bartunkova, J. and Smrz, D. (2020) Tumoral and Paratumoral NK Cells and CD8+ T Cells of Esophageal Carcinoma Patients Express High Levels of Cd47. Scientific Reports, 10, Article No. 13936. [Google Scholar] [CrossRef] [PubMed]
[21] 于爽. NLRP3炎症小体参与食管鳞癌增殖、侵袭和迁移并介导荷瘤小鼠顺铂抵抗[D]: [博士学位论文]. 郑州: 郑州大学, 2020.
[22] 谭健安. CD47基因对食道癌细胞增殖的影响[J]. 基因组学与应用生物学, 2019, 38(1): 484-488.
[23] 吴兵, 李世升, 肖商荣, 等. CD47-siRNA通过调控ROS诱导食管癌细胞SEG-1凋亡[J]. 现代生物医学进展, 2019, 19(11): 2061-2065.
[24] 张一鸣. CD47和SIRPα在食管鳞状细胞癌中的表达及临床意义[D]: [硕士学位论文]. 郑州: 郑州大学, 2019.
[25] Zhao, C., Yu, S., Wang, S., Li, S., Wang, Z. and Han, S. (2017) Characterization of Cluster of Differentiation 47 Expression and Its Potential as a Therapeutic Target in Esophageal Squamous Cell Cancer. Oncology Letters, 15, 2017-2023. [Google Scholar] [CrossRef] [PubMed]
[26] 谭晓琴. 食管鳞癌放射敏感性相关miRNA的筛选及验证[D]: [硕士学位论文]. 泸州: 泸州医学院, 2014.
[27] Yang, C., Cao, F. and He, Y. (2023) An Immune-Related Gene Signature for Predicting Survival and Immunotherapy Efficacy in Esophageal Adenocarcinoma. Medical Science Monitor, 29, e940157. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, J., Huang, S., Zhang, L., Liu, Z., Liang, R., Jiang, S., et al. (2019) Combined Prognostic Value of the Cancer Stem Cell Markers CD47 and CD133 in Esophageal Squamous Cell Carcinoma. Cancer Medicine, 8, 1315-1325. [Google Scholar] [CrossRef] [PubMed]
[29] Suzuki, S., Yokobori, T., Tanaka, N., Sakai, M., Sano, A., Inose, T., et al. (2012) CD47 Expression Regulated by the miR-133a Tumor Suppressor Is a Novel Prognostic Marker in Esophageal Squamous Cell Carcinoma. Oncology Reports, 28, 465-472. [Google Scholar] [CrossRef] [PubMed]
[30] Tao, H., Qian, P., Wang, F., Yu, H. and Guo, Y. (2017) Targeting CD47 Enhances the Efficacy of Anti-Pd-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 25, 1579-1587. [Google Scholar] [CrossRef] [PubMed]
[31] Li, N., Hembat, K., Ma, X., et al. (2019) Purification of Anti-CD47 Specific Antibody from Camel Serum by Immunoaffinity Chromatography. Genomics and Applied Biology, 38, 1012-1017.
[32] 席欧彦, 贾二坷, 赵婷, 等. 抗CD47单链抗体制备及抗原结合活性分析[J]. 生物技术, 2017, 27(4): 370-377.
[33] 席欧彦. 抗CD47基因工程抗体对实验小鼠肿瘤治疗的研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆大学生物学, 2017.
[34] Eladl, E., Tremblay-LeMay, R., Rastgoo, N., Musani, R., Chen, W., Liu, A., et al. (2020) Role of CD47 in Hematological Malignancies. Journal of Hematology & Oncology, 13, Article No. 96. [Google Scholar] [CrossRef] [PubMed]
[35] Jia, X., Yan, B., Tian, X., Liu, Q., Jin, J., Shi, J., et al. (2021) CD47/SIRPα Pathway Mediates Cancer Immune Escape and Immunotherapy. International Journal of Biological Sciences, 17, 3281-3287. [Google Scholar] [CrossRef] [PubMed]

为你推荐